LATISSE is a Ophthalmic Solution/ Drops in the Human Prescription Drug category. It is labeled and distributed by Allergan, Inc.. The primary component is Bimatoprost.
Product ID | 0023-3616_476e4325-4bd9-4086-be6b-b9044c57e480 |
NDC | 0023-3616 |
Product Type | Human Prescription Drug |
Proprietary Name | LATISSE |
Generic Name | Bimatoprost |
Dosage Form | Solution/ Drops |
Route of Administration | OPHTHALMIC |
Marketing Start Date | 2009-01-26 |
Marketing Category | NDA / NDA |
Application Number | NDA022369 |
Labeler Name | Allergan, Inc. |
Substance Name | BIMATOPROST |
Active Ingredient Strength | 0 mg/mL |
Pharm Classes | Prostaglandin Analog [EPC],Prostaglandins [CS] |
NDC Exclude Flag | N |
Listing Certified Through | 2021-12-31 |
Marketing Start Date | 2009-01-26 |
NDC Exclude Flag | N |
Sample Package? | N |
Marketing Category | NDA |
Application Number | NDA022369 |
Product Type | HUMAN PRESCRIPTION DRUG |
Billing Unit | ML |
Marketing Start Date | 2009-01-26 |
Marketing Category | NDA |
Application Number | NDA022369 |
Product Type | HUMAN PRESCRIPTION DRUG |
Marketing Start Date | 2009-01-26 |
Marketing Category | NDA |
Application Number | NDA022369 |
Product Type | HUMAN PRESCRIPTION DRUG |
Billing Unit | ML |
Marketing Start Date | 2009-01-26 |
Marketing Category | NDA |
Application Number | NDA022369 |
Product Type | HUMAN PRESCRIPTION DRUG |
Billing Unit | ML |
Marketing Start Date | 2009-01-26 |
Marketing Category | NDA |
Application Number | NDA022369 |
Product Type | HUMAN PRESCRIPTION DRUG |
Marketing Start Date | 2012-08-02 |
Marketing End Date | 2013-01-07 |
Marketing Category | NDA |
Application Number | NDA022369 |
Product Type | HUMAN PRESCRIPTION DRUG |
Marketing Start Date | 2009-01-26 |
Marketing Category | NDA |
Application Number | NDA022369 |
Product Type | HUMAN PRESCRIPTION DRUG |
Billing Unit | ML |
Marketing Start Date | 2009-01-26 |
Marketing Category | NDA |
Application Number | NDA022369 |
Product Type | HUMAN PRESCRIPTION DRUG |
Marketing Start Date | 2009-01-26 |
Marketing Category | NDA |
Application Number | NDA022369 |
Product Type | HUMAN PRESCRIPTION DRUG |
Marketing Start Date | 2009-01-26 |
Ingredient | Strength |
---|---|
BIMATOPROST | .3 mg/mL |
SPL SET ID: | 34f83d9d-2c64-463e-8a90-9a460fedfead |
Manufacturer | |
UNII | |
RxNorm Concept Unique ID - RxCUI | |
PHarm Class EPC | |
NUI Code |
NDC | Brand Name | Generic Name |
---|---|---|
0023-3616 | LATISSE | bimatoprost |
0781-6206 | Bimatoprost | Bimatoprost |
42571-128 | BIMATOPROST | BIMATOPROST |
50383-908 | Bimatoprost | Bimatoprost |
50383-912 | Bimatoprost | Bimatoprost |
57297-429 | bimatoprost | bimatoprost |
60505-0583 | Bimatoprost | Bimatoprost |
62332-507 | Bimatoprost | Bimatoprost |
62332-511 | bimatoprost | bimatoprost |
65862-802 | Bimatoprost | Bimatoprost |
68083-295 | Bimatoprost | Bimatoprost |
68083-296 | Bimatoprost | Bimatoprost |
68083-439 | Bimatoprost | Bimatoprost |
0023-9652 | DURYSTA | bimatoprost |
0023-3205 | LUMIGAN | bimatoprost |
Mark Image Registration | Serial | Company Trademark Application Date |
---|---|
LATISSE 77921801 not registered Dead/Abandoned |
Wet Enterprises, Inc. 2010-01-27 |
LATISSE 77449970 3620623 Live/Registered |
Allergan, Inc. 2008-04-16 |